



Oncology Pharmacist Lunch & Lecture Webinar Series

Thursdays

12:00 pm - 1:00 pm (EST)

August 6

August 20

September 3

September 17

Register online at
www.msho.org.

AGENDA

August 6

New Drug Updates: IV Therapies

Angela Duenn, PharmD, BCOP

This presentation will provide pharmacists practicing in various settings an overview of the anticancer drug approvals in 2019. The presentation will also discuss relevant clinical trial findings and their utility in clinical practice.

CEU Information:

Live Activity:

ACPE Universal Activity #0112-9999-20-307-L01-P & #0112-9999-20-307-L01-T

Home Study Activity:

ACPE Universal Activity #0112-9999-20-307-H01-P & #0112-9999-20-307-H01-T

1.0 Contact Hour; Knowledge-based Activity

Initial Release Date: 8/6/20; Expiration Date: 8/6/21

August 20

New Drug Updates: Oral Oncolytics

Claire Saadeh, PharmD, BCOP

Approximately 25% of the new chemotherapy drugs coming up for FDA approval are oral oncolytics. It is important to keep up with these drugs to ensure that patients are receiving the correct agent based on specific mutations within cancer cells, and the appropriate dosing is employed. These agents also require comprehensive patient education, adherence monitoring, safety monitoring, and side effect management that pharmacists and technicians should be familiar with.

CEU Information:

Live Activity:

ACPE Universal Activity #0112-9999-20-308-L01-P & #0112-9999-20-308-L01-T

Home Study Activity:

ACPE Universal Activity #0112-9999-20-308-H01-P & #0112-9999-20-308-H01-T

1.0 Contact Hour; Knowledge-based Activity

Initial Release Date: 8/6/20; Expiration Date: 8/6/21

September 3

Updates in Treatment of Pancreatic Cancer

Allison Schepers, PharmD, BCOP

This presentation will review the evidence and controversies surrounding the treatment of localized and metastatic pancreatic cancer, with a focus on pharmacologic therapy. Topics will include adjuvant chemotherapy options, role of neoadjuvant treatment, novel therapeutic modalities such as pegilodecakin and pegvorhialuronidase alfa, and the role of targeted therapies such as PARP inhibitors. The presenter will also discuss the role of genetic testing in patients with pancreatic cancer.

CEU Information:

Live Activity:

ACPE Universal Activity #0112-9999-20-309-L01-P & #0112-9999-20-309-L01-T

Home Study Activity:

ACPE Universal Activity #0112-9999-20-309-H01-P & #0112-9999-20-309-H01-T

1.0 Contact Hour; Knowledge-based Activity

Initial Release Date: 8/6/20; Expiration Date: 8/6/21

September 17

Recent Advances in the Treatment of Breast Cancer

Ryan DasGupta, PharmD

Pharmacists will attain the knowledge about evolving breast cancer treatments (new drugs or indications, dosing, monitoring, side effects and management, costs, etc.) Pharmacy technicians will attain familiarity with new drugs that have been approved to improve their confidence and competence regarding selection and preparation of drugs.

CEU Information:

Live Activity:

ACPE Universal Activity #0112-9999-20-310-L01-P & #0112-9999-20-310-L01-T

Home Study Activity:

ACPE Universal Activity #0112-9999-20-310-H01-P & #0112-9999-20-310-H01-T

1.0 Contact Hour; Knowledge-based Activity

Initial Release Date: 8/6/20; Expiration Date: 8/6/21

FACULTY

Ryan DasGupta, PharmD
*Clinical Pharmacy Specialist,
Hematology/Oncology*
Henry Ford Health System
Detroit, MI

Angela Duenn, PharmD, BCOP
*Regional Clinical Pharmacy
Coordinator, Hematology-Oncology*
St. Joseph Mercy Health System
Ypsilanti, MI

Claire Saadeh, PharmD, BCOP
Professor, Pharmacy Practice
Ferris State University
Sparrow Health System
DeWitt, MI

Allison Schepers, PharmD, BCOP
*Clinical Pharmacist Specialist,
Medical Oncology*
University of Michigan
College of Pharmacy
Ann Arbor, MI

Intended Audience

This continuing education program was designed specifically for pharmacists and pharmacy technicians.

Pharmacist and Technician Learning Objectives

At the end of this activity, participants should be able to:

New Drug Updates: IV Therapies

1. Recall recently approved anticancer drugs.
2. Discuss novel mechanisms of drug action.
3. Describe relevant clinical findings and their utility in clinical practice.
4. Describe the impact of new drug approvals in cancer care.

New Drug Updates: Oral Oncolytics

5. Identify the mechanism of action of novel oral oncolytic agents.
6. Discuss the most common and significant side effects associated with the newly approved oral oncolytic agents.
7. Summarize the current place in therapy for newly approved oral cancer drugs.

Updates in Treatment of Pancreatic Cancer

8. Evaluate the role of genetic testing and use of PARP inhibitors in patients with pancreatic adenocarcinoma.
9. Summarize recent practice-changing trials in the neoadjuvant and adjuvant settings.
10. Describe novel treatment strategies in the metastatic setting, including maintenance therapy and novel targeted therapies.

Recent Advances in the Treatment of Breast Cancer

11. Review pathophysiology of breast cancer including relevant biomarkers that influence medication selection.
12. Discuss the safety and efficacy of novel pharmacologic treatment strategies for various subtypes of breast cancer.
13. Identify supportive care strategies to manage common and rare toxicities of breast cancer treatments.

PHARMACY CONTINUING EDUCATION REQUIREMENTS

These activities are structured to meet knowledge-based educational needs and acquires factual knowledge. Information in knowledge-type activities is based on evidence as accepted in the literature by the health care professions. Pharmacy continuing education (PCE) credit will be earned based on participation in this activity. Attendance and participation are required before obtaining PCE credit. **Any individual who is more than 10 minutes late to an activity or leaves an activity early will not be granted PCE credit. This procedure will be strictly enforced, so please plan accordingly.**

Participants of the live programs must complete online activity evaluations and posttests with a passing score of 70 percent or greater no later than 14 days after each program date. Participants of the home studies must complete online activity evaluations and posttests with a passing score of 70 percent or greater no later than Nov. 30, 2020. . Posttests will not be graded and credit will not be processed until the online evaluation and posttest has officially closed for response. Please allow MPA two weeks to grade posttests and process and upload credit to CPE Monitor after the posttest has closed. NOTE: ACPE guidelines prohibit MPA from issuing credit more than 60 days after the activity for any reason; therefore, to avoid denial of credit, it is imperative that pharmacists and pharmacy technicians complete the online evaluation and posttest by the deadline indicated to allow sufficient time for processing. If all requirements are met, participants will receive pharmacy continuing education (PCE) credit through CPE Monitor, a national, collaborative effort by ACPE and the National Association of Boards of Pharmacy (NABP) to provide an electronic system for pharmacists and pharmacy technicians to track their completed PCE credits. MPA, as an ACPE-accredited provider, is required to report pharmacist and pharmacy technician PCE credit using this tracking system. Pharmacist and pharmacy technician participants must provide their NABP e-Profile identification number and date of birth (in MMDD format) when they complete activity evaluations. It will be the responsibility of the participant to provide the correct information. If this information is not correctly provided, NABP and ACPE prohibit MPA from issuing CPE credit. Online access to their inventory of completed credits will allow pharmacists and pharmacy technicians to easily monitor their compliance with CPE requirements and print statements of credit. Therefore, MPA will not provide printed statements of credit to pharmacists and pharmacy technicians. **Partial credit will not be awarded.** If you have yet to sign up for CPE Monitor, go to MyCPEMonitor.net.



Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

PLANNING COMMITTEE

Stephanie Dunseith, PharmD
Clinical Pharmacist Specialist
St. John Specialty Pharmacy
Farmington Hills, MI

Angela G. German, PharmD, BCOP
*PGY2 Oncology Pharmacy Residency Director
Clinical Pharmacy Specialist -
Hematology/Oncology*
Henry Ford Hospital
Detroit, MI

Shannon Hough, PharmD, BCOP
Clinical Pharmacist Coordinator, Ambulatory Oncology Initiatives
University of Michigan
Ann Arbor, MI

Polly E. Kintzel, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist for Adult Oncology
Spectrum Health
Grand Rapids, MI

Diana Kostoff, PharmD, BCPS, BCOP
*Coordinator - Hematology/Oncology Ambulatory Clinical Services
Clinical Pharmacy Specialist - Hematology/Oncology*
Henry Ford Cancer Institute
Henry Ford Hospital
Detroit, MI

Stephen T. Smith, MS, RPh, FASHP
Chief Pharmacy Officer
Karmanos Cancer Institute
Karmanos Cancer Network
Detroit, MI

Mary Kay Makarewicz
Executive Director
Michigan Society of Hematology
and Oncology
Troy, MI